Patients with underlying diseases such as uncontrolled diabetes, hypertension, and cardiovascular disease, as well as the elderly, are more prone to severe clinical consequences, as well as a higher rate of COVID-19-related complications (
17,
18). According to evidence, diabetes, especially in men, the elderly, senescence obesity, high blood pressure, and heart disease, predisposes people to the development of COVID-19 with severe and lethal consequences such as accumulation of cytokines, thrombose, and eventually death. Many patients in India had diabetic ketoacidosis as the first presentation of the disease. COVID-19 in diabetic patients causes severe hyperglycemia. Infection with the coronavirus can also cause high blood sugar symptoms in people with an unmasked diabetes condition. Ten percent of patients with COVID-19 with no history of diabetes develop high blood sugar after COVID-19 infection, which can be due to the detrimental effects of the virus on the pancreas. Approximately one-third of coronavirus deaths occur in people with diabetes (
19). A study in Hong Kong showed that in 115 patients with SARS-CoV, the diabetes mortality rate increased (
20). Also, in 2009, the results of a study demonstrated severe complications during the influenza A (H1N1) epidemic in people with diabetes (
21). In another study on MERS-CoV, the results showed that approximately 50% of 637 patients infected with the virus had diabetes (
3). The presence of diabetes in patients with COVID-19 depends on the study population. Statistical studies in China demonstrated that in a study of 1,099 patients with COVID-19, 7.4% had diabetes (
22).
In a meta-analysis study in 2019, the results of 7 studies involving 1,576 patients from China demonstrated that after hypertension, diabetes was the second most common comorbidity in patients with COVID-19, and about 9.7% of patients had diabetes (
23). In a study in Italy, an analysis of COVID-19 consequences in 1591 patients admitted to the intensive care unit demonstrated that the rates of underlying diseases in hospitalized patients were: blood pressure (49%), cardiovascular disorders (21%), high cholesterol (18%) and diabetes (17%) (
24). The results of observational studies demonstrated that the leading cause of death in patients with COVID-19 was diabetes, and the complications of COVID-19 in people with diabetes were very severe, which could be responsible for various complications in these patients (
25). Since diabetes is associated with immune system disorders, diabetics are more likely to contract infections than non-diabetics. Uncontrolled hyperglycemia in diabetics can lead to degenerative changes, decreased phagocytosis, endovascular adhesion to the endothelium, and decreased intracellular bactericidal activity (
26). Also, uncontrolled diabetes can lead to complications such as vascular injuries and subsequent neuropathic injuries, which can cause infection in diabetics (
27). Diabetes and obesity are associated with chronic inflammation caused by increased secretion of adipose tissue leptin and cytokines hormones such as tumor necrosis factor α (TNFα) and interleukin 6 (IL-6), which play an essential role in insulin resistance (
28). The results of several studies indicate that diabetes has adverse effects on patients’ clinical outcomes. However, these results are not conclusive and need further investigation. Several studies have demonstrated that diabetes is a significant determinant of adverse clinical outcomes in patients with COVID-19 (
6). According to the results of some studies, acute hyperglycemia is associated with the risk of COVID-19. This new hypothesis has been the focus of much research during the current epidemic, and similar studies will continue in this field. Yang et al. and Mirzaei et al. reported that during the previous SARS epidemic, diabetes and hyperglycemia were associated with poor prognoses (
29,
30). In a 2015 study on ICU patients, Liao et al. found that stress-induced hyperglycemia was an independent and related factor in increasing the risk of death in nondiabetic patients (
31). In a study on diabetic patients admitted to the ICU between 2011 and 2014, it was observed that levels of glycated hemoglobin A or hemoglobin A1c (HbA1c) in people with a glucose gap greater than 80 mg/dL were significantly higher in deceased patients than in diabetics with a glucose gap less than 80 mg/dL. Among the identified causes of death in the mentioned study, 38.8% were related to respiratory failures, and 59.5% were related to underlying infections (
31). Researchers have suggested that HIV AIDS is important in predicting mortality in critically ill patients. In these studies, the severity of HIV AIDS has been linked to the severity of the disease. In humans, stress-induced hyperglycemia (SIH) can transform severe adaptive responses to a serious illness that can cause the body to over-release cytokines and anti-regulatory hormones, resulting in insulin resistance (
32). Controlled diabetes with regular quarterly monitoring of HbA1c levels can play an important role in managing the disease in people with diabetes and keeping the body free from inflammation. In a 2020 study by Raufi et al., they examined the effects of good and poor diabetes control in 117 COVID-19 patients with diabetes and reported that 79.5% of patients had poor management, and 20.5% had good glycemic control (
33). Nonetheless, CT scan images in the two groups were not significantly different. The observed mortality and recovery rates were also the same in both groups. This indicates that the outcomes of the study could be more reliable according to the results of HbA1c. Since this study was observational, the results cannot be compared with the results of another study, and they may seem contradictory (
33,
34).